Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for Alzheimer's disease. The company is focused on advancing sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers (AβOs), which are believed to be a key driver of Alzheimer's disease pathology. Acumen's scientific founders pioneered research on AβOs, and the company is leveraging this expertise to develop a novel treatment option that could slow cognitive decline and improve outcomes for patients.

Acumen has a strong commitment to innovation and is actively engaged in clinical trials. The company is currently conducting the ALTITUDE-AD study, a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of sabirnetug. This trial builds upon the positive results of the INTERCEPT-AD study, a Phase 1 clinical trial that demonstrated rapid, direct target engagement of AβOs and a favorable safety profile. Acumen's dedicated team of scientists and professionals are committed to translating scientific breakthroughs into effective treatments for people with Alzheimer's disease.

Acumen Pharmaceuticals offers a hybrid work environment, allowing employees to work both remotely and in the office. While many team members are located near the company's headquarters in Newton, MA, and have the option for a hybrid work schedule, Acumen embraces technology to enable seamless collaboration among team members, regardless of their location. They aim to bring employees together for work and fun events a few times a year, demonstrating their commitment to building a strong and connected team.

Acumen Pharmaceuticals provides a comprehensive benefits package to its employees, including medical, dental, and vision insurance, a health savings account with employer contributions, flexible time off, company holidays, a 401(k) plan with a company match, short and long-term disability insurance, life insurance, and paid parental leave for all new parents. This package is designed to support the well-being of employees and their families.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for Alzheimer's disease. The company believes that toxic amyloid beta oligomers (AβOs) are a key driver of Alzheimer's pathology and are focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets these toxic AβOs. Acumen's mission is to deliver treatments that can truly impact those affected by Alzheimer's disease, aiming to slow cognitive and functional decline and preserve quality time for patients and their loved ones.

Acumen Pharmaceuticals fosters an inclusive and respectful work environment, prioritizing teamwork and collaboration. They believe in empowering employees to do their best work, embracing their diverse perspectives and encouraging a culture of creativity and innovation. The company prioritizes a people-first approach, valuing employees and their well-being, demonstrated through competitive compensation and benefits programs.

Acumen Pharmaceuticals prioritizes inclusivity and embraces the diversity of its employees. They believe in creating a culture where every employee feels valued and respected, regardless of background. Their approach focuses on "cultural add" rather than "fit," recognizing the unique strengths each individual brings to the team. They actively promote diversity within their workforce and strive to create a supportive environment where everyone can thrive.